0001179110-20-011838.txt : 20201211
0001179110-20-011838.hdr.sgml : 20201211
20201211180842
ACCESSION NUMBER: 0001179110-20-011838
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201209
FILED AS OF DATE: 20201211
DATE AS OF CHANGE: 20201211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MCLAUGHLIN KEVIN F
CENTRAL INDEX KEY: 0001214938
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 201384628
MAIL ADDRESS:
STREET 1: C/O ACCELERON PHARMA INC.
STREET 2: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2020-12-09
0
0001280600
ACCELERON PHARMA INC
XLRN
0001214938
MCLAUGHLIN KEVIN F
128 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
SVP, CFO and Treasurer
Common Stock
2020-12-09
4
M
0
548
41.20
A
11764
D
Common Stock
2020-12-09
4
M
0
400
27.97
A
12164
D
Common Stock
2020-12-09
4
M
0
1051
30.17
A
13215
D
Common Stock
2020-12-09
4
M
0
1873
40.61
A
15088
D
Common Stock
2020-12-09
4
S
0
3872
125.03
D
11216
D
Common Stock
2020-12-10
4
M
0
100
41.20
A
11316
D
Common Stock
2020-12-10
4
M
0
200
27.97
A
11516
D
Common Stock
2020-12-10
4
M
0
100
30.17
A
11616
D
Common Stock
2020-12-10
4
M
0
100
40.61
A
11716
D
Common Stock
2020-12-10
4
S
0
500
125.12
D
11216
D
Common Stock
2020-12-11
4
M
0
3100
41.20
A
14316
D
Common Stock
2020-12-11
4
S
0
3100
125.00
D
11216
D
Option to Purchase Common Stock
41.20
2020-12-09
4
M
0
548
0
D
2025-01-08
Common Stock
548
10452
D
Option to Purchase Common Stock
27.97
2020-12-09
4
M
0
400
0
D
2026-03-03
Common Stock
400
7900
D
Option to Purchase Common Stock
30.17
2020-12-09
4
M
0
1051
0
D
2027-03-02
Common Stock
1051
30249
D
Option to Purchase Common Stock
40.61
2020-12-09
4
M
0
1873
0
D
2028-03-01
Common Stock
1873
28952
D
Option to Purchase Common Stock
41.20
2020-12-10
4
M
0
100
0
D
2025-01-08
Common Stock
100
10352
D
Option to Purchase Common Stock
27.97
2020-12-10
4
M
0
200
0
D
2026-03-03
Common Stock
200
7700
D
Option to Purchase Common Stock
30.17
2020-12-10
4
M
0
100
0
D
2027-03-02
Common Stock
100
30149
D
Option to Purchase Common Stock
40.61
2020-12-10
4
M
0
100
0
D
2028-03-01
Common Stock
100
28852
D
Option to Purchase Common Stock
41.20
2020-12-11
4
M
0
3100
0
D
2025-01-08
Common Stock
3100
7252
D
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.27 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after the grant.
The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2016.
The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2017.
The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2018.
/s/ Adam M. Veness, as attorney-in-fact for Kevin F. McLaughlin
2020-12-11